JP2017528462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528462A5 JP2017528462A5 JP2017513177A JP2017513177A JP2017528462A5 JP 2017528462 A5 JP2017528462 A5 JP 2017528462A5 JP 2017513177 A JP2017513177 A JP 2017513177A JP 2017513177 A JP2017513177 A JP 2017513177A JP 2017528462 A5 JP2017528462 A5 JP 2017528462A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- antibody
- composition according
- antibody comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 23
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 16
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 206010066476 Haematological malignancy Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 229960004942 lenalidomide Drugs 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 102000052645 human CD38 Human genes 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047877P | 2014-09-09 | 2014-09-09 | |
| US62/047,877 | 2014-09-09 | ||
| US201462087287P | 2014-12-04 | 2014-12-04 | |
| US62/087,287 | 2014-12-04 | ||
| PCT/US2015/048899 WO2016040294A2 (en) | 2014-09-09 | 2015-09-08 | Combination therapies with anti-cd38 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086765A Division JP2020143108A (ja) | 2014-09-09 | 2020-05-18 | 抗ｃｄ３８抗体による併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528462A JP2017528462A (ja) | 2017-09-28 |
| JP2017528462A5 true JP2017528462A5 (enExample) | 2018-10-11 |
| JP6707531B2 JP6707531B2 (ja) | 2020-06-10 |
Family
ID=55436472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513177A Active JP6707531B2 (ja) | 2014-09-09 | 2015-09-08 | 抗ｃｄ３８抗体による併用療法 |
| JP2020086765A Pending JP2020143108A (ja) | 2014-09-09 | 2020-05-18 | 抗ｃｄ３８抗体による併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086765A Pending JP2020143108A (ja) | 2014-09-09 | 2020-05-18 | 抗ｃｄ３８抗体による併用療法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20160067205A1 (enExample) |
| EP (1) | EP3191187B1 (enExample) |
| JP (2) | JP6707531B2 (enExample) |
| KR (1) | KR102586588B1 (enExample) |
| CN (1) | CN108064182B (enExample) |
| AU (1) | AU2015315396B2 (enExample) |
| BR (1) | BR112017004614A2 (enExample) |
| CA (1) | CA2960494C (enExample) |
| CL (1) | CL2017000559A1 (enExample) |
| CR (1) | CR20170086A (enExample) |
| EA (1) | EA035979B1 (enExample) |
| EC (1) | ECSP17021175A (enExample) |
| ES (1) | ES2890669T3 (enExample) |
| GT (1) | GT201700048A (enExample) |
| IL (1) | IL251033B (enExample) |
| MA (1) | MA40608A (enExample) |
| MX (1) | MX386886B (enExample) |
| MY (1) | MY192918A (enExample) |
| NI (1) | NI201700027A (enExample) |
| PE (1) | PE20170676A1 (enExample) |
| PH (1) | PH12017500442B1 (enExample) |
| SG (1) | SG11201701867SA (enExample) |
| UA (1) | UA122212C2 (enExample) |
| WO (1) | WO2016040294A2 (enExample) |
| ZA (1) | ZA201702483B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| JP7160533B2 (ja) | 2015-05-13 | 2022-10-25 | モルフォシス・アーゲー | 多発性骨髄腫（ｍｍ）の処置 |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| TWI724046B (zh) * | 2016-04-06 | 2021-04-11 | 美商健生生物科技公司 | 以抗ｃｄ３８抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療 |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| TW201823471A (zh) * | 2016-10-06 | 2018-07-01 | 美商錫羅斯製藥公司 | 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法 |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| US12371506B2 (en) | 2018-01-12 | 2025-07-29 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of anti-CD38 antibodies |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| BR112021016923A2 (pt) | 2019-02-27 | 2021-11-03 | Genentech Inc | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits |
| CN113993543B (zh) | 2019-06-10 | 2024-07-12 | 武田药品工业株式会社 | 使用抗cd38抗体的组合疗法 |
| GB201916150D0 (en) * | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| WO2021092171A1 (en) | 2019-11-06 | 2021-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| CN119317641A (zh) | 2022-05-11 | 2025-01-14 | 基因泰克公司 | 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药 |
| KR20250039386A (ko) | 2022-07-13 | 2025-03-20 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 |
| TW202413433A (zh) | 2022-07-19 | 2024-04-01 | 美商建南德克公司 | 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| AU2024270495A1 (en) | 2023-05-05 | 2025-10-09 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2025106474A1 (en) | 2023-11-14 | 2025-05-22 | Genentech, Inc. | Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2026030464A1 (en) | 2024-07-30 | 2026-02-05 | Genentech, Inc. | Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992001049A2 (en) | 1990-07-13 | 1992-01-23 | The General Hospital Corporation | Cd53 cell surface antigen and use thereof |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1998016245A1 (fr) | 1996-10-15 | 1998-04-23 | Shionogi & Co., Ltd. | Procede de determination d'un auto-anticorps |
| WO1998016254A1 (en) | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
| DE69831224T2 (de) | 1997-05-02 | 2006-03-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| US7223397B1 (en) * | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| AU6541801A (en) | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6955884B2 (en) | 2000-10-17 | 2005-10-18 | Trudeau Institute, Inc. | Methods for identifying compounds that inhibit CD38 activity |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| NZ536746A (en) * | 2002-06-13 | 2007-02-23 | Crucell Holland Bv | An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor |
| US7767429B2 (en) | 2003-03-05 | 2010-08-03 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| WO2004111233A1 (ja) | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS |
| ES2346978T3 (es) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple. |
| ES2378767T3 (es) | 2003-12-23 | 2012-04-17 | Crucell Holland B.V. | Molécula de unión humana contra CD1a |
| ES2541436T3 (es) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| AU2006329944A1 (en) | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2049109B1 (en) | 2006-08-02 | 2015-11-18 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| AU2007302448C1 (en) | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| CN101970003A (zh) | 2007-11-09 | 2011-02-09 | 诺华有限公司 | 抗cd40抗体的应用 |
| WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2009221916A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| KR101280716B1 (ko) | 2008-03-25 | 2013-07-01 | 로슈 글리카트 아게 | 비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도 |
| EP2662090A1 (en) | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| HRP20151168T1 (hr) | 2008-11-07 | 2015-12-04 | Amgen Research (Munich) Gmbh | Lijeäśenje akutne limfoblastiäśne leukemije |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SMT202000092T1 (it) | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| CN102655853B (zh) | 2009-09-17 | 2015-07-29 | 巴克斯特卫生保健有限公司 | 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法 |
| AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| US20130137134A1 (en) | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| NZ607473A (en) * | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CL2013001944A1 (es) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| ES2658953T3 (es) * | 2012-09-25 | 2018-03-13 | Morphosys Ag | Combinaciones y usos de los mismos |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| WO2014142220A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | 抗腫瘍剤 |
| US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| JP2016534090A (ja) | 2013-07-15 | 2016-11-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ３８アゴニストの医学的使用 |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| WO2015067570A2 (en) | 2013-11-06 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US10106620B2 (en) | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
-
2015
- 2015-09-08 PE PE2017000431A patent/PE20170676A1/es unknown
- 2015-09-08 JP JP2017513177A patent/JP6707531B2/ja active Active
- 2015-09-08 CA CA2960494A patent/CA2960494C/en active Active
- 2015-09-08 EP EP15839752.1A patent/EP3191187B1/en active Active
- 2015-09-08 SG SG11201701867SA patent/SG11201701867SA/en unknown
- 2015-09-08 US US14/847,428 patent/US20160067205A1/en not_active Abandoned
- 2015-09-08 MX MX2017003115A patent/MX386886B/es unknown
- 2015-09-08 AU AU2015315396A patent/AU2015315396B2/en active Active
- 2015-09-08 EA EA201790548A patent/EA035979B1/ru unknown
- 2015-09-08 KR KR1020177009199A patent/KR102586588B1/ko active Active
- 2015-09-08 CR CR20170086A patent/CR20170086A/es unknown
- 2015-09-08 MY MYPI2017700796A patent/MY192918A/en unknown
- 2015-09-08 PH PH1/2017/500442A patent/PH12017500442B1/en unknown
- 2015-09-08 UA UAA201703276A patent/UA122212C2/uk unknown
- 2015-09-08 CN CN201580060898.4A patent/CN108064182B/zh active Active
- 2015-09-08 BR BR112017004614-8A patent/BR112017004614A2/pt not_active Application Discontinuation
- 2015-09-08 MA MA040608A patent/MA40608A/fr unknown
- 2015-09-08 WO PCT/US2015/048899 patent/WO2016040294A2/en not_active Ceased
- 2015-09-08 ES ES15839752T patent/ES2890669T3/es active Active
-
2016
- 2016-12-21 US US15/386,391 patent/US10604580B2/en active Active
-
2017
- 2017-03-08 NI NI201700027A patent/NI201700027A/es unknown
- 2017-03-08 CL CL2017000559A patent/CL2017000559A1/es unknown
- 2017-03-08 IL IL251033A patent/IL251033B/en unknown
- 2017-03-09 GT GT201700048A patent/GT201700048A/es unknown
- 2017-04-06 EC ECIEPI201721175A patent/ECSP17021175A/es unknown
- 2017-04-07 ZA ZA2017/02483A patent/ZA201702483B/en unknown
-
2020
- 2020-05-18 JP JP2020086765A patent/JP2020143108A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507953A5 (enExample) | ||
| JP2017507954A5 (enExample) | ||
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| HRP20192058T1 (hr) | Kombinirane terapije s anti-cd38 antitijelima | |
| JP2018520101A5 (enExample) | ||
| JP2021526136A5 (enExample) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| HRP20231021T1 (hr) | Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije | |
| RU2010143454A (ru) | Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения не-ходжкинских лимфом | |
| CN108064182B (zh) | 采用抗cd38抗体的联合疗法 | |
| JP2018534933A5 (enExample) | ||
| HRP20201001T1 (hr) | Metode za liječenje tumora pomoću cd3xcd20 bispecifičnog antitijela | |
| ECSP15017314A (es) | Formulacion de anticuerpos | |
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| WO2021024020A1 (en) | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer | |
| EP3302550A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| EP3337506B1 (en) | Combinations and uses thereof | |
| JP2019533682A5 (enExample) | ||
| CN105407921A (zh) | 包含抗cd38抗体和卡非佐米的组合物 | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| CN111246881A (zh) | Pd-1抗体用于治疗肿瘤的用途 | |
| JP2013543869A5 (enExample) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| US10478497B2 (en) | Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer |